Clinigen Group plc Issue of Equity (5457B)
09 October 2020 - 2:00AM
UK Regulatory
TIDMCLIN
RNS Number : 5457B
Clinigen Group plc
08 October 2020
8 October 2020
Issue of Equity
Clinigen Group plc (AIM: CLIN, the "Group") announces that it
has made an application for the admission to trading on AIM of
129,876 ordinary shares of 0.1 pence each in the Group (the "New
Ordinary Shares"). These New Ordinary Shares have been issued to
satisfy share options vesting under The 2017 Clinigen Group
Sharesave Plan and rank pari passu with the existing shares of the
Group. Admission to trading on AIM of the New Ordinary Shares is
anticipated to occur on 13 October 2020.
At admission the issued share capital of the Group will consist
of 133,028,647 ordinary shares, with no shares held in treasury.
The total number of voting rights in the Group will therefore be
133,028,647. This figure may be used by shareholders as the
denominator to determine if they are required to notify their
interests in, or a change to their interests in, the Group under
the Disclosure Guidance and Transparency Rules.
-Ends-
Contact details
Clinigen Group plc Tel: +44 (0) 1283 495010
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
Matt Parrish, Head of Investor Relations
J.P.Morgan Cazenove - Nominated Adviser Tel: +44 (0) 20 7260
& Joint Broker 1000
James Mitford / Hemant Kapoor
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653
4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0) 20 7457
2020
Melanie Toyne-Sewell / Phillip Marriage Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. The Group has sites in North America,
Europe, Africa and the Asia Pacific region.
Clinigen now has over 1,150 employees across five continents in
14 countries, with supply and distribution hubs and operational
centres of excellence in key long term growth regions. The Group
works with 21 of the top 25 pharmaceutical companies; interacting
with over 18,000 registered users across 115 countries, shipping
approximately 6.5 million units in the year.
For more information on Clinigen, please visit
www.clinigengroup.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFSIFEAESSEFS
(END) Dow Jones Newswires
October 08, 2020 11:00 ET (15:00 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024